Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nitin Jain, MD, Gail J. Roboz, MD, Marina Konopleva, MD PhD, Hongtao Liu, MD PhD, Elias Jabbour, MD, Camille Poirot, Pharm.D., Cécile Schiffer-Manniou, PhD, Agnès Gouble, PhD, Asifa Haider, PhD, Oleg Zernovak, MD, Richard A. Larson, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-138594

Published: 2020

Journal Articles

Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease

Blood (2019) 134 (Supplement_1): 2659.

https://doi.org/10.1182/blood-2019-126869

Published: 2019

Journal Articles

Pre-Clinical Activity of Allogeneic Anti-CD22 CAR-T Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia

Julia Wells, PhD, Tianyu Cai, PhD, Cécile Schiffer-Manniou, PhD, Stéphanie Filipe, PhD, Agnès Gouble, PhD, Roman Galetto, PhD, Nitin Jain, MD, Elias J. Jabbour, MD, Julianne Smith, PhD, Marina Konopleva, MD PhD

Blood (2017) 130 (Supplement 1): 808.

https://doi.org/10.1182/blood.V130.Suppl_1.808.808

Published: 2017

Journal Articles

Pre-Clinical Studies of Allogeneic Anti-CD123 CAR T-Cells for the Therapy of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Tianyu Cai, PhD, Roman Galetto, PhD, Agnès Gouble, PhD, Julianne Smith, PhD, Antonio Cavazos, MSc, Lina Han, PhD, Qi Zhang, PhD MD, Vinitha Mary Kuruvilla, Sergej Naumovich Konoplev, MD PhD, Sattva S. Neelapu, MD, Andrew A. Lane, MD PhD, Monica L. Guzman, PhD, Hagop M. Kantarjian, MD, Naveen Pemmaraju, MD, Marina Konopleva, MD PhD

Blood (2017) 130 (Supplement 1): 2625.

https://doi.org/10.1182/blood.V130.Suppl_1.2625.2625

Published: 2017

Journal Articles

Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma

Rohit Mathur, PhD, Zheng Zhang, Jin He, Roman Galetto, PhD, Agnès Gouble, PhD, Isabelle Chion-Sotinel, Stéphanie Filipe, PhD, Annabelle Gariboldi, Tanooha Veeramachaneni, Elisabet E. Manasanch, MD, Sheeba K. Thomas, MD, Hans C. Lee, MD, Krina K. Patel, MDMSc, Donna M. Weber, MD, R. Eric Davis, MD, Robert J. Orlowski, MD PhD, Julianne Smith, PhD, Jing Yang, PhD, Sattva S. Neelapu, MD

Blood (2017) 130 (Supplement 1): 502.

https://doi.org/10.1182/blood.V130.Suppl_1.502.502

Published: 2017

Journal Articles

Selection and Characterization of Antibody Clones Are Critical for Accurate Flow Cytometry-Based Monitoring of CD123 in Acute Myeloid Leukemia

Nicole M. Cruz, MD, Linda Lam, Mayumi Sugita, MD, Roman Galetto, PhD, Agnès Gouble, PhD, Julianne Smith, PhD, Gail J. Roboz, Monica L. Guzman, PhD

Blood (2016) 128 (22): 1693.

https://doi.org/10.1182/blood.V128.22.1693.1693

Published: 2016

Journal Articles

Gene Editing of the Human Pklr Gene in Human Hematopoietic Progenitors to Correct Pyruvate Kinase Deficiency

Oscar Quintana-Bustamante, Sara Fañanas, Israel Orman, Agnès Gouble, PhD, Roman Galetto, PhD, Laurent Poirot, PhD, Juan A. Bueren, PhD, Jose C. Segovia, PhD

Blood (2016) 128 (22): 3513.

https://doi.org/10.1182/blood.V128.22.3513.3513

Published: 2016

Journal Articles

Allogeneic Tcrα/β Deficient CAR T-Cells Targeting CD123 Prolong Overall Survival of AML Patient-Derived Xenografts

Monica L. Guzman, PhD, Mayumi Sugita, MD, Hongliang Zong, MD PhD, Nathan Ewing-Crystal, Vicenta Trujillo-Alonso, Nuria Mencia-Trinchant, PhD, Linda Lam, Nicole M. Cruz, MD, Roman Galetto, PhD, Agnès Gouble, PhD, Duane C Hassane, PhD, Julianne Smith, PhD, Gail J. Roboz

Blood (2016) 128 (22): 765.

https://doi.org/10.1182/blood.V128.22.765.765

Published: 2016

Journal Articles

Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Tianyu Cai, PhD, Roman Galetto, PhD, Agnès Gouble, PhD, Julianne Smith, PhD, Antonio Cavazos, MS, Sergej Konoplev, MD PhD, Andrew A. Lane, MD PhD, Monica L. Guzman, PhD, Hagop M. Kantarjian, MD, Naveen Pemmaraju, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 4039.

https://doi.org/10.1182/blood.V128.22.4039.4039

Published: 2016

Journal Articles

Bypassing the Constraint for Chimeric Antigen Receptor (CAR) Development in T-Cells Expressing the Targeted Antigen: Improvement of Anti-CS1 CAR Activity in Allogenic TCRa/CS1 Double Knockout T-Cells for the Treatment of Multiple Myeloma (MM)

Roman Galetto, PhD, Isabelle Chion-Sotinel, Agnès Gouble, PhD, Julianne Smith, PhD

Blood (2015) 126 (23): 116.

https://doi.org/10.1182/blood.V126.23.116.116

Published: 2015

Journal Articles

TCRab Deficient CAR T-Cells Targeting CD123: An Allogeneic Approach of Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia (AML)

Roman Galetto, PhD, Céline Lebuhotel, Agnès Gouble, PhD, Nuria Mencia-Trinchant, PhD, Cruz M Nicole, MD, Gail J. Roboz, MD, Monica L. Guzman, PhD, Julianne Smith, PhD

Blood (2015) 126 (23): 2555.

https://doi.org/10.1182/blood.V126.23.2555.2555

Published: 2015

Journal Articles

T-Cell Engineering For “off-The-shelf” Adoptive Immunotherapy

Laurent Poirot, PhD, Cécile Schiffer-Mannioui, PhD, Brian Philip, Sophie Derniame, PhD, Agnes Gouble, PhD, Isabelle Chion-Sotinel, PhD, Diane Le Clerre, Laetitia Lemaire, Stéphanie Grosse, PhD, Gordon Cheung, Sylvain Arnould, PhD, Julianne Smith, PhD, Martin Pule, MD, Andrew Scharenberg, PhD

Blood (2013) 122 (21): 1661.

https://doi.org/10.1182/blood.V122.21.1661.1661

Published: 2013

NARROW

Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease

Pre-Clinical Activity of Allogeneic Anti-CD22 CAR-T Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia

Pre-Clinical Studies of Allogeneic Anti-CD123 CAR T-Cells for the Therapy of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma

Selection and Characterization of Antibody Clones Are Critical for Accurate Flow Cytometry-Based Monitoring of CD123 in Acute Myeloid Leukemia

Gene Editing of the Human Pklr Gene in Human Hematopoietic Progenitors to Correct Pyruvate Kinase Deficiency

Allogeneic Tcrα/β Deficient CAR T-Cells Targeting CD123 Prolong Overall Survival of AML Patient-Derived Xenografts

Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Bypassing the Constraint for Chimeric Antigen Receptor (CAR) Development in T-Cells Expressing the Targeted Antigen: Improvement of Anti-CS1 CAR Activity in Allogenic TCRa/CS1 Double Knockout T-Cells for the Treatment of Multiple Myeloma (MM)

TCRab Deficient CAR T-Cells Targeting CD123: An Allogeneic Approach of Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia (AML)

T-Cell Engineering For “off-The-shelf” Adoptive Immunotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only